Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM) — Sagar Lonial (2018) | RDL Network
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Sagar Lonial, Meletios A Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Sabeen Mekan, Oumar Sy, Anil Singhal, Paul G. Richardson
Sagar Lonial, Meletios A Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Suresh G. Shelat, Oumar Sy, Anil Singhal, Paul G. Richardson
Sagar Lonial, Paul G. Richardson, María‐Victoria Mateos, Katja Weisel, Meletios A Dimopoulos, Philippe Moreau, Oumar Sy, Jessica Katz, Manish Gupta, Antonio Palumbo
Meletios A Dimopoulos, Katja Weisel, Sagar Lonial, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Alex Ganetsky, Ying‐Ming Jou, Mihaela Popa McKiver, Anil Singhal, Paul G. Richardson
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kazuyuki Suzuki, Marc‐Steffen Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, Suresh G. Shelat, Michael Robbins, B. Rafferty, Jesús F. San Miguel
Discussion(0)
No comments yet. Be the first to comment.